ORMP - オラメド・ファ―マシュ―ティカルズ (Oramed Pharmaceuticals Inc.)

ORMPのニュース

   Oramed Pharmaceuticals Inc. (ORMP) produces promising results  2023/03/03 13:24:00 US Post News
A share of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) closed at $2.13 per share on Thursday, down from $2.20 day before. While Oramed Pharmaceuticals Inc. has underperformed by -3.18%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ORMP fell by -78.48%, with highs and lows ranging from $13.73 […]
   Wondrous stocks: BP p.l.c. (NYSE:BP 1.93%), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -0.95%)  2023/02/24 13:24:24 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Wondrous stocks: BP p.l.c. (NYSE:BP 1.93%), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -0.95%) appeared first on Stocks Equity .
   Wondrous stocks: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -1.36%), Ouster, Inc. (NYSE:OUST -1.29%)  2023/02/13 07:18:32 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Wondrous stocks: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -1.36%), Ouster, Inc. (NYSE:OUST -1.29%) appeared first on Stocks Equity .
   Exploring Growth Opportunities In Oramed Pharmaceuticals Inc. (NASDAQ: ORMP)  2023/02/09 15:00:00 Stocks Register
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares, rose in value on Wednesday, 02/08/23, with the stock price up by 1.46% to the previous day’s close as strong demand from buyers drove the stock to $2.08. Actively observing the price movement in the last trading, the stock closed the session at $2.05, falling within a range of $2.025 … Exploring Growth Opportunities In Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Read More »
   Astonishing stocks: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -1.44%), Draganfly Inc. (NASDAQ:DPRO -12.77%)  2023/02/08 11:46:15 Stock Equity
ORMP has seen its SMA50 which is now -70.74%. In looking the SMA 200 we see that the stock has seen a -69.77%. DPRO has seen its SMA50 which is … The post Astonishing stocks: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -1.44%), Draganfly Inc. (NASDAQ:DPRO -12.77%) appeared first on Stocks Equity .
   Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Is Down -83.87% So Far This Year. Analysts Expect A Significant Price Rally  2023/01/30 16:30:00 Stocks Register
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) price closed higher on Friday, January 27, jumping 0.52% above its previous close. A look at the daily price movement shows that the last close reads $1.93, with intraday deals fluctuated between $1.89 and $1.955. The company’s 5Y monthly beta was ticking 2.32. Taking into account the 52-week price action we … Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Is Down -83.87% So Far This Year. Analysts Expect A Significant Price Rally Read More »
   Surprising stocks: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -6.31%), Citius Pharmaceuticals, Inc. (NASDAQ:CTXR 6.50%)  2023/01/27 14:18:11 Stock Equity
ORMP has seen its SMA50 which is now -75.75%. In looking the SMA 200 we see that the stock has seen a -72.34%. CTXR has seen its SMA50 which is … The post Surprising stocks: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -6.31%), Citius Pharmaceuticals, Inc. (NASDAQ:CTXR 6.50%) appeared first on Stocks Equity .
   Oramed Pharmaceuticals Inc. (NASDAQ:ORMP): Buy, Sell Or Hold At $1.93?  2023/01/27 14:00:00 Marketing Sentinel
In last trading session, Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) saw 2.2 million shares changing hands with its beta currently measuring 2.08. Company’s recent per share price level of $1.93 trading at -$0.13 or -6.31% at ring of the bell on the day assigns it a market valuation of $77.30M. That closing price of ORMP’s stock is … Oramed Pharmaceuticals Inc. (NASDAQ:ORMP): Buy, Sell Or Hold At $1.93? Read More »
   Pleasing stocks: Siyata Mobile Inc. (NASDAQ:SYTA -2.53%), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP 0.98%)  2023/01/26 14:14:01 Stock Equity
SYTA has seen its SMA50 which is now 1.05%. In looking the SMA 200 we see that the stock has seen a -72.59%. ORMP has seen its SMA50 which is … The post Pleasing stocks: Siyata Mobile Inc. (NASDAQ:SYTA -2.53%), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP 0.98%) appeared first on Stocks Equity .
   Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Drops -10.22%: This $89.24 million Stock Cry -1632.67%  2023/01/18 14:00:00 Stocks Register
The trading price of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) closed lower on Tuesday, January 17, closing at $2.02, -10.22% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $1.92 and $2.16. In examining the 52-week price action we see that the stock hit a 52-week … Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Drops -10.22%: This $89.24 million Stock Cry -1632.67% Read More »
   Looking Into Oramed Pharmaceuticals''s Return On Capital Employed  2022/12/22 14:48:45 Benzinga
According to Benzinga Pro data, during Q3, Oramed Pharmaceuticals (NASDAQ: ORMP ) posted sales of $682 thousand. Earnings were up 34.46%, but Oramed Pharmaceuticals still reported an overall loss of $7.25 million. In Q2, Oramed Pharmaceuticals brought in $1.34 million in sales but lost $11.07 million in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a … Full story available on Benzinga.com
   Was anything positive for Oramed Pharmaceuticals Inc. (ORMP) stock last session?  2022/12/22 12:40:00 US Post News
The share price of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) rose to $9.46 per share on Wednesday from $8.28. While Oramed Pharmaceuticals Inc. has overperformed by 14.25%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ORMP fell by -39.20%, with highs and lows ranging from $15.80 to $3.59, […]
   Oramed: NASH Biotech Play With Added Bonus  2022/12/07 08:49:24 Seeking Alpha
Oramed achieved positive results from phase 2 study using ORMD-0801 for Type 2 Diabetes patients with NASH. See why ORMP stock is a Strong Buy.
   Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism  2022/11/29 13:40:00 PR Newswire
NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an…
   Oramed Pharma Up After Positive Clinical Data  2022/11/18 10:43:40 TipRanks
Shares of Oramed Pharmaceuticals (NASDAQ: ORMP) were on an upswing in pre-market trading on Friday as the clinical-stage pharmaceutical company announced additional positive data from its Phase 2 study of its oral insulin candidate (ORMD-0801). This Phase 2 study was a double-blind, fully randomized, placebo-controlled, multicenter clinical trial (ORA-D-N02) to assess the safety and efficacy of ORMD-0801 when it comes to the reduction of liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis (NASH). This study indicated that ORMD-0801 achieved the primary endpoint of safety and tolerability and the oral insulin candidate achieved "consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids.

calendar